GLP-1 drugs on every 2026 Puerto Rico Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 3 stand-alone Part D plans in Puerto Rico cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
| Drug | HealthSpring Extra Rx$50.00/moS5617-385 | HealthSpring Assurance Rx$65.70/moS5617-348 | AARP Medicare Rx Preferred from UHC$145.10/moS5820-037 |
|---|---|---|---|
| Ozempicsemaglutide injection | Tier 3PA17%QL 3/28d | Tier 3PA22%QL 3/28d | Tier 3PA25%QL 3/28d |
| Mounjarotirzepatide injection | Tier 3PA17%QL 2/28d | Tier 3PA22%QL 2/28d | Tier 3PA25%QL 2/28d |
| Trulicitydulaglutide injection | Tier 3PA17%QL 2/28d | Tier 3PA22%QL 2/28d | Tier 3PA25%QL 2/28d |
| Ozempic tabletsoral semaglutide, formerly Rybelsus | Tier 3PA17%QL 30/30d | Tier 3PA22%QL 30/30d | Tier 3PA25%QL 30/30d |
| Wegovysemaglutide, weight | Not covered | Not covered | Not covered |
| Zepboundtirzepatide, weight | Not covered | Not covered | Not covered |
| Victozaliraglutide | Not covered | Not covered | Not covered |
| liraglutidegeneric Victoza | Not covered | Not covered | Not covered |
| Saxendaliraglutide, weight | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). | ||
| Byettaexenatide | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). | ||
| Bydureon BCiseexenatide extended-release | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). | ||
| orforglipronoral GLP-1, approved 2026 | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). | ||
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.